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Despite their different biological behaviour, canine acute leukaemia (AL) and chronic lymphocytic 
leukaemia (CLL) are both characterized by an abnormal cellular proliferation, replacing normal bone 
marrow tissue and subsequently invading different organs and blood (Adam et al., 2009). Matrix 
metalloproteinases (MMPs) are involved in the proteolytic degradation of extracellular matrix (ECM). 
Tumour cells can secrete MMPs to promote invasion and metastatic spread (Giantin et al., 2012), as well as 
tissue inhibitors of metalloproteinases (TIMPs), which control the proteolytic activity of MMPs. MT1-
MMP mediates the activation of pro-MMP-2 (Egeblad and Werb, 2002). RECK, an endogenous MMP 
inhibitor, down-regulates MMP-2, MMP-9 and MT1-MMP (Takagi  et al., 2005). Vascular endothelial 
growth factor (VEGF) is one of the most potent angiogenic promoters (Takahashi and Shibuya,  2005). 
The present study assessed the expression profiles of the MMP-2, MMP-9, MT1-MMP, TIMP-1, TIMP-
2, RECK, VEGF-A and VEGF-164 transcripts and the protein levels of MMP-2, MMP-9 and VEGF-A in 
canine leukaemias. 
Clinical, clinicopathological and immunophenotypic data were obtained by complete blood cell count 
with leukocyte differential count and flow cytometric analysis and were used to classify leukaemia samples 
(Gelain et al., 2010). Blood samples from six healthy dogs matched according to age, breed and gender 
served as control for immunocytochemistry and extracted lymphocytes for quantitative real-time RT-PCR 
(qRT-PCR). Target gene expression was evaluated as previously described (Giantin et al., 2012). The 
concentration of each set of primers was optimised to efficiently amplify its target (see Table 1 of 
Supplementary material, Appendix A). Data were expressed as relative quantification values if the target 
gene was undetectable or not quantifiable in control lymphocytes (CTRL), while as fold changes if the 
target gene was quantifiable in CTRL. 
Protein expression levels of MMP-2, MMP-9, and VEGF-A were evaluated by immunocytochemistry. 
The intensity (0–3) and the percentage of immunoassayed tumour cells were assessed for each antibody in 
ten randomly selected fields at 400 magnification. The total score for each examined field was obtained by 
multiplying the intensity score by the percentage. A final ratio was obtained after averaging the ten selected 
fields (Giantin et al., 2012). Statistical analysis was performed by using the Mann–Whitney test and the 
Kruskal–Wallis test followed by Dunn’s post-test for qRT-PCR and immunocytochemistry data. A non-
parametric Spearman correlation analysis was used to determine the different correlations. Statistical 
significance was set at P < 0.05. 
Eleven female dogs with AL were included. All dogs showed anaemia, thrombocytopenia and 
leucocytosis; median age was 8 years (range, 2–12 years). Two dogs were diagnosed with T-acute 
lymphoblastic leukaemia (ALL) (CD34+CD5+), 2 with B-ALL (CD34+CD79a+) and 7 with acute 
undifferentiated leukaemia (CD34+CD45+). Twelve dogs were diagnosed with T-CLL: 8 CD8+, 1 CD4+, 1 
CD21+ and 2 CD4 CD8 . There were 10 males and 2 females; median age was 10 years (range, 5–13 
years). All dogs showed leukocytosis; six of them were anaemic. The median percentage values (range) of 
blasts in blood were 98.1% (72–100%) and 88.2% (72–96%) of the total nucleated cells for AL and CLL, 
respectively. 
Concerning qRT-PCR (Tables 1 and 2), TIMP-2 and MT1-MMP mRNA levels were significantly higher 
in AL than CLL. In CLL, significant positive correlations were found between MMP-9 and VEGF mRNAs 
(P < 0.01; Spearman r = 0.75) and between MMP-9 and TIMP-1 mRNAs (P < 0.05, Spearman r = 0.62). 
Negative correlations were found between the percentage of neoplastic cells in CLL and MMP-9 mRNA (P 
< 0.01; Spearman r = 0.74), VEGF mRNA (P < 0.05; Spearman r = 0.59), TIMP-1 mRNA (P < 0.05, 
Spearman r = 0.62) and TIMP-2 mRNA (P < 0.05, Spearman r = 0.65). The percentage of blasts was 
negatively correlated with MMP-9 mRNA in AL (P < 0.05; Spearman r = 0.70). Concerning immunocyto-
chemical analysis (Table 3), a significant difference was observed between the control peripheral blood and 
the leukaemia blood samples for VEGF, MMP-9 and MMP-2 ( Figs. 1 a,b,c and 2 a,b,c). 
Angiogenesis and invasion play an essential role in haematopoietic tumours in people (Moehler et al., 
2003). Several molecules, in particular MMPs, TIMPs and VEGF, regulate invasion and dissemination of 
neoplastic cells. In our study, MMP-9 mRNA was not quantifiable and the protein was not expressed in 
control lymphocytes; whereas higher MMP-9 transcript and protein levels were present in CLL compared to 
AL. In this contest, leukaemic cells might express and activate MMP-9 for transendothelial migration and 
basement membrane invasion. 
VEGF was over-expressed at the mRNA and protein level in both AL and CLL with respect to controls; 
furthermore, their protein values were higher in CLL compared to AL. We hypothesise that VEGF in 
leukaemic cells could stimulate new blood vessels growth, and subsequently increase endothelium 
permeability and cell motility leading to systemic dissemination (Letilovic et al., 2006). We also 
demonstrated a significant positive correlation between VEGF and MMP-9 mRNA levels in CLL samples. 
VEGF may stimulate MMP-9 secretion by acting as an autocrine factor, and subsequently MMP-9 may 
release different angiogenic factors that bind to ECM in a sort of vicious circle. 
AL and CLL over-expressed TIMP-1 transcript; this data might confirm the role of TIMP-1 as 
stimulating growth factor secreted by neoplastic cells. A significant positive correlation was also 
demonstrated in CLL between MMP-9 and TIMP-1. This is not surprising because MMP-9 is frequently 
found to be coexpressed in neoplastic cells together with TIMP-1. MT1-MMP transcript was significantly 
higher in AL than CLL, supporting its aggressive behaviour. MT1-MMP is crucial for cancer cell growth 
and tissue invasion (Hotary et al., 2003). The inverse correlation between blasts percentage and mRNA data 
may be explained by the influence of residual normal leukocytes in the expression of these genes. 
Limitations of this study include the small population size, the use of immunocytochemistry to quantify 
protein expression, and the limited value of mRNA in investigating MMPs, which are regulated at different 
levels. Currently, synthetic MMP inhibitors have demonstrated efficacy in various models of tumour 
metastasis and invasion, thereby showing the role of MMPs as therapeutic target. Further studies are 
warranted to test their antitumoural efficacy in dogs with leukaemia. 
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Table 1  
MMP-9, MMP-2, TIMP-2 and RECK mRNA expression in AL and CLL blood samples. 
 
Target genes AL CLL P 
    
MMP-9 0.20 ± 0.19 0.59 ± 0.64 0.1891 
MMP-2 n.d. n.d. – 
TIMP-2 5.28 ± 3.94 0.51 ± 0.60 0.0043 
RECK 0.11 ± 0.12 0.23 ± 0.19 0.1611 
 
Quantitative real time RT-PCR data are expressed in arbitrary units (mean ± SD) as relative quantification 
values (RQ). Mann–Whitney test.  
Target gene expression was not quantifiable in control lymphocytes. n.d. = not detectable.  
AL = acute leukaemias.  
CLL = chronic lymphocytic leukaemia. 
!
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Table 2 
MT1-MMP, TIMP-1, VEGF-A and VEGF-164 mRNA expression in AL and CLL blood samples.  
Target genes AL CLL P 
    
MT1-MMP 1.20 ± 0.91 0.36 ± 0.48 0.0316 
TIMP-1 0.39 ± 0.25 0.77 ± 0.72 0.2485 
VEGF-A 2.55 ± 3.17 3.19 ± 3.57 0.8777 
VEGF-164 4.10 ± 5.05 4.07 ± 4.75 0.7818 
 
Quantitative real-time RT-PCR data are expressed in arbitrary units (mean ± SD) as fold changes vs. 
control lymphocytes. Mann–Whitney test. 
A fold change equal to 1 was assumed for control lymphocytes. AL = acute leukaemia. 
CLL = chronic lymphocytic leukaemia. 
 
 
 
Table 3 
Immunostaining score values for MMP-9, MMP-2 and VEGF-A expressed as the mean (range). 
 
 Control peripheral blood AL CLL P 
     
MMP-9 0.66±0.51 78.11 ± 64.48 104.1 ± 36.8 0.0009 
MMP-2 0.16 ± 0.40 56 ± 53.5 71.73 ± 35.51 0.0008 
VEGF-A 0.5 ± 0.54 21.33 ± 23.62 27.9 ± 15.62 0.0008 
 
Results are expressed as products of intensity and index of immunoassayed tumor cells (0–300). Mann–
Whitney test. 
AL = acute leukaemia. 
CLL = chronic lymphocytic leukaemia. 
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Fig. 1. ALL. Peripheral blood. (a) plasma cells and lymphoid leukaemia cells brown immunostained for 
MMP-2 (arrow); (b) lymphoid leukaemia cells intensely immunostained for MMP-9 (arrow); and (c) 
VEGF (arrow). Immunocytochemistry, (bar = 70 lm). 
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Fig. 2. CLL. Peripheral blood. lymphoid leukaemia cells intensely and diffusely brown immunostained for 
(a) MMP-2 (arrow), (b) MMP-9 (arrow), and (c) VEGF (arrow). Immunocytochemistry, (bar = 70 lm). 
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